180 results on '"Lacout, Catherine"'
Search Results
2. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
3. Caspase Inhibition Modulates Monocyte-Derived Macrophage Polarization in Damaged Tissues
4. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
5. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation
6. A major role of TGF-β1 in the homing capacities of murine hematopoietic stem cell/progenitors
7. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes
8. Combined Biological and Modeling Approach of Hematopoiesis: From Native to Stressed Erythropoiesis
9. The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation
10. Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells
11. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice
12. A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset
13. BCR–ABL activates STAT3 via JAK and MEK pathways in human cells
14. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
15. The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5
16. A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome
17. Modeling the Behavior of Hematopoietic Compartments from Stem to Red Cells in Murine Steady State and Stress Hematopoiesis
18. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
19. MIR150 Is Involved in the Monocyte Subset Differentiation and Its Down-Regulation Leads to Classical Monocyte Accumulation in Chronic Myelomonocytic Leukemia
20. HSP27: A Therapeutic Target in Myelofibrosis
21. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice
22. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice
23. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
24. Ligand-independent Thrombopoietin Mutant Receptor Requires Cell Surface Localization for Endogenous Activity
25. Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis
26. Use Of 46/1 Haplotype Permits To Follow JAK2V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment
27. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
28. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.
29. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
30. 46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2V617F clonal Architecture in PV Patients
31. Platelet Phenotype and Thrombosis In JAK2V617F Mice
32. JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect
33. LYL-1 deficiency induces a stress erythropoiesis
34. Interferon-Alpha Preferentially Targets JAK2V617F-Positive Rather Than Wild-Type Early Progenitor Cells in Myeloproliferative Disorders.
35. Constitutive Heterozygous Expression of JAK2V617F Mutated Kinase Triggers Severe Myeloproliferative Disorder in Knock-in Mice.
36. Ligand-independent Thrombopoietin Mutant Receptor Requires Cell Surface Localization for Endogenous Activity
37. Constitutive TGF-β1 Deficiency Induces a Defect in Hematopoietic Stem/Progenitor Cell Compartment in Fetus and Neonate.
38. Ligand-Independent MPLW515L Activity Requires Cell Surface Localization
39. P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1
40. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice
41. Adenoviral-mediated TGF-β1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development
42. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
43. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
44. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor
45. Proteasome Inhibitor Bortezomib Can Inhibit Bone Marrow Fibrosis Development in a Murine Model of Myelofibrosis.
46. Constitutive Activation of STAT5 and Bcl-XL Overexpression Can Induce Endogenous Erythroid Colony Formation in Human Primary Cells.
47. Role for the Nuclear Factor κB Pathway in Transforming Growth Factor-β1 Production in Idiopathic Myelofibrosis: Possible Relationship with FK506 Binding Protein 51 Overexpression
48. Role of the Transcription Factor LYL-1 in the Adult and Fetal Hematopoietic Stem Cells.
49. Hemostatic disorders in a JAK2V617F -driven mouse model of myeloproliferative neoplasm.
50. Thrombopoietin (TPO) Knockout Phenotype Induced by Cross-Reactive Antibodies Against TPO Following Injection of Mice with Recombinant Adenovirus Encoding Human TPO
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.